Keyphrases
Multiple Myeloma
100%
Non-Hodgkin Lymphoma
100%
Autologous Transplantation
100%
Tumor Cell Mobilization
100%
Transplantation
50%
Granulocyte Colony-stimulating Factor (G-CSF)
50%
Diagnostic Tool
25%
Clinical Outcomes
25%
Response Rate
25%
Hematological Malignancies
25%
Progression-free Survival
25%
Tumor Cells
25%
Overall Survival
25%
Chemotherapy
25%
Stem Cells
25%
Reconstitution
25%
Peripheral Blood
25%
Minimal Residual Disease
25%
Blood Cells
25%
Impact Response
25%
High-dose Chemotherapy
25%
Contamination Risk
25%
Autologous Peripheral Blood Stem Cells
25%
Mobilization Regimen
25%
Peripheral Blood Hematopoietic Stem Cells
25%
Medicine and Dentistry
Tumor Cell
100%
Non-Hodgkin Lymphoma
100%
Autotransplantation
100%
Multiple Myeloma
100%
Cytokine
40%
Granulocyte Colony Stimulating Factor
40%
Diagnosis
20%
Hematologic Malignancy
20%
Progression Free Survival
20%
Overall Survival
20%
Minimal Residual Disease
20%
Stem Cell
20%
High Dose Chemotherapy
20%
Peripheral Blood Stem Cell
20%
Hematopoietic Cell
20%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Multiple Myeloma
100%
Nonhodgkin Lymphoma
100%
Cytokine
40%
Granulocyte Colony Stimulating Factor
40%
Progression Free Survival
20%
Hematologic Malignancy
20%
Overall Survival
20%
Chemotherapy
20%
High Dose Chemotherapy
20%
Minimal Residual Disease
20%
Immunology and Microbiology
Tumor Cell
100%
Multiple Myeloma
100%
Autotransplantation
100%
Cytokine
40%
Granulocyte Colony-Stimulating Factor
40%
Hematopoietic Cell
20%
Drug Megadose
20%
Stem Cell
20%
Overall Survival
20%
Peripheral Blood Stem Cell
20%
Progression Free Survival
20%